SCHEMBL3622577

SCHEMBL3622577

CC[C@H](N)C(O)c1nnc(-c2cccnc2)o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.48
RAB9A P51151 7/20 0.48
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 5/20 0.45
HPGD P15428 4/20 0.45
HSD17B10 Q99714 4/20 0.45
MAPK1 P28482 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KMT2A Q03164 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
PTGS2 P35354 1/20 0.44
CA2 P00918 1/20 0.43
HTT P42858 2/20 0.42
TP53 P04637 2/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5946144 1.00 NPC1 (0.48) NPC1RAB9AALDH1A1KDM4EHPGD
SCHEMBL3622574 1.00 NPC1 (0.48) NPC1RAB9AALDH1A1KDM4EHPGD
SCHEMBL5398496 0.88 NPC1 (0.44) NPC1RAB9AALDH1A1KDM4EHPGD
SCHEMBL5457842 0.85 SMN1; SMN2 (0.50) NPC1RAB9AALDH1A1KDM4EHPGD
SCHEMBL3621024 0.85 SMN1; SMN2 (0.50) NPC1RAB9AALDH1A1KDM4EHPGD
SCHEMBL3621026 0.85 SMN1; SMN2 (0.50) NPC1RAB9AALDH1A1KDM4EHPGD
SCHEMBL3623134 0.84 PKM (0.47) NPC1RAB9AALDH1A1KDM4EHPGD
SCHEMBL3623132 0.84 PKM (0.47) NPC1RAB9AALDH1A1KDM4EHPGD
SCHEMBL17516274 0.76 NPC1 (0.59) NPC1RAB9AALDH1A1KDM4EHPGD
SCHEMBL6402847 0.76 NPC1 (0.52) NPC1RAB9AALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662849-B2 Amidino compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2010-02-16 US disclosed
US-7662849-B2 Amidino compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2010-02-16 US disclosed
US-7662849-B2 Amidino compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2010-02-16 US disclosed
US-20070276019-A1 Haloalkyl Containing Compounds as Cysteine Protease Inhibitors AXYS PHARMACEUTICALS, INC. (US) 2007-11-29 US disclosed
US-20070276019-A1 Haloalkyl Containing Compounds as Cysteine Protease Inhibitors AXYS PHARMACEUTICALS, INC. (US) 2007-11-29 US disclosed
US-20070276019-A1 Haloalkyl Containing Compounds as Cysteine Protease Inhibitors AXYS PHARMACEUTICALS, INC. (US) 2007-11-29 US disclosed
US-20060264464-A1 Amidino compounds as cysteine protease inhibitors QUEST DIAGNOSTICS INVESTMENTS LLC 2006-11-23 US disclosed
WO-2005028454-A1 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed
WO-2004108661-A1 AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264464-A1 Amidino compounds as cysteine protease inhibitors CTSF, CTSB, CTSS NPC1 264/4885RAB9A 966/4885ALDH1A1 4189/4885
US-20070276019-A1 Haloalkyl Containing Compounds as Cysteine Protease Inhibitors CTSF, CTSS, CTSE NPC1 123/4885RAB9A 978/4885ALDH1A1 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.